Approval · Notice of Compliance 3523 · 2003
CRESTOR: Notice of Compliance 3523
Issued February 16, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3523
- Date
- February 16, 2003
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
Medicinal ingredients
- ROSUVASTATIN CALCIUM 10 MG per TAB
- ROSUVASTATIN CALCIUM 20 MG per TAB
- ROSUVASTATIN CALCIUM 40 MG per TAB